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L I N K  TO  O R I G I N A L  A RT I C L E
The interaction between a drug and its bio-
logical target is a key step in the causal chain 
between drug dosing and drug effect in the 
human body. The strength of this interaction 
may be represented by the drug–target dis-
sociation constant (Kd), which describes the 
drug concentration that results in 50% target 
occupancy (that is, the percentage of target 
molecules that are bound to a drug molecule) 
at equilibrium. However, the value of Kd does 
not provide information on the rate at which 
target binding equilibrium is reached after a 
change in the drug concentration. The kinet-
ics of target binding are most simply described 
by two rate constants: the second-order asso-
ciation rate constant kon and the first-order 
dissociation rate constant koff  (FIG. 1a).
Drug–target residence time, defined as 
1/koff, has received increasing attention in drug 
discovery following the publication of an arti-
cle by Copeland and colleagues in 2006 that 
discussed the beneficial effect of a long dis-
sociative half-life of a drug–target complex 
(defined as ln[2]/koff) on (selective) prolon-
gation of target occupancy and thus of phar-
macological effects1. Since the publication of 
this paper, we and others have highlighted 
some limitations of the simple drug–target 
residence time model and the interpretation 
of its results; for examples, see REFS2–5. The 
aim of this article, which is based on previ-
ous research from our group4, is to illustrate 
the impact of the role of target saturation 
(that is, target occupancy close to 100%) on 
the prolongation of target occupancy and to 
show that lack of consideration of this role 
may contribute to inaccurate conclusions 
about the influence of drug–target binding 
kinetics on the duration of target occupancy. 
In particular, a value of koff that is lower than 
the pharmacokinetic elimination rate con-
stant (kel) may not be the key determinant of 
the duration of target occupancy as the target 
becomes closer to being saturated. We also 
discuss examples that help illustrate how to 
take into account the role of target saturation 
in decisions about whether or not to select 
drug candidates with low koff values (that is, 
long drug–target residence times).
Importance of target saturation
When different compounds for which a reduc-
tion in koff is accompanied by an increased 
affinity are compared, increased in  vivo 
duration of target occupancy is expected 
based on the increased affinity alone, if the 
tested concentrations are similar and lead to 
an initial target occupancy close to 100%. As 
a consequence, the increased duration of drug 
action that is observed in such a comparison 
cannot be attributed to the koff but is purely 
dependent on the Kd, the pharmacokinetics 
and the administered dose. An example of 
such a comparison is given in FIG. 1b, where 
we took the koff, kon and elimination half-life 
values of the HIV protease inhibitors ampre-
navir, lopinavir and atazanavir from REF.5 and 
simulated their target occupancy. The com-
pounds with the lowest koff values, lopinavir 
and atazanavir, also had increased affinities 
and showed an increased duration of target 
occupancy. As can be clearly seen in FIG. 1b, 
the increased duration of target occupancy is 
only the consequence of a rightward shift in 
the occupancy–time curve and thus only the 
consequence of the Kd. To demonstrate this, 
we overlaid the simulations of lopinavir and 
atazanavir with simulations of hypothetical 
compounds that have the same Kd values as 
lopinavir and atazanavir, but the koff value of 
amprenavir.
An example where a decrease in koff does 
lead to an additional increase in the dura-
tion of target occupancy compared with the 
affinity-driven increase in target occupancy 
is given in FIG. 1c. In this simulation, we took 
the koff, kon and elimination half-life values 
of ipratropium, aclidinium and PF-3635659 
from REF.5 and REF.6 and simulated their target 
occupancy at the muscarinic M3 receptor.  The 
compounds with the lowest koff values, acli-
dinium and PF-3635659, also had increased 
affinities and showed an increased duration 
of target occupancy. However, the increased 
duration of target occupancy in FIG. 1c is not 
only the consequence of a rightward shift in 
the occupancy–time curve and is therefore not 
only the consequence of the increased Kd. To 
demonstrate this, we overlaid the simulations 
with simulations of hypothetical compounds 
that have the same Kd values as aclidinium and 
PF-3635659, but the koff value of ipratropium. 
These hypothetical compounds only showed 
a rightward shift of the occupancy–time curve 
and had considerably shorter duration of tar-
get occupancy compared with aclidinium and 
PF-3635659, respectively.
Another example of a decrease in koff that 
leads only to an affinity-driven prolongation 
of target occupancy is given in the initial opin-
ion article of Copeland and colleagues1, in 
which the increasing duration of target occu-
pancy was (incorrectly) used to dem onstrate 
the influence of drug–target residence time. 
In these simulations, the koff values are all 
much higher than the elimination rate con-
stant and the decrease in koff only results in a 
rightward shift of the occupancy–time curve, 
as in FIG. 1b.
The fact that a higher drug concentration 
or increased affinity leads to an increased 
duration of drug effects has been described 
in quantitative terms since the early days of 
pharmacokinetic/pharmacodynamic (PK/PD) 
modelling7. More recently, the relationship 
between target saturation and the duration 
of target occupancy has also been discussed 
more quantitatively with respect to drug– 
target binding kinetics; for example, see 
REFS4,8. In a previous publication4, we inves-
tigated with mathematical approximations 
when drug–target dissociation (that is, koff) 
becomes the rate-limiting step for the dura-
tion of drug action compared with pharma-
cokinetics, target saturation and rebinding 
(that is, the influence of target binding on 
the drug concentration around the target). 
Although the influence of target saturation 
on the duration of target occupancy is math-
ematically well defined, the relevance of target 
saturation for the influence of koff on the dura-
tion of target occupancy has not been a focus 
of previous articles and has been ignored in 
several papers focusing on the influence of koff 
on target occupancy.
To find the koff value that gives a signifi-
cant prolongation of target occupancy, we 
identified previously for what values of target 
occupancy the elimination rate constant (kel) 
of the drug from plasma would have less influ-
ence on the duration of target occupancy than 
koff4 (that is, for what values the koff is the main 
determinant of the duration of target occu-
pancy). We performed this approximation by 
assuming that the slowest step on the path of 
target dissociation and free drug elimination 
determines the decline rate of target occu-
pancy. To do this analysis correctly, target 
saturation needs to be taken into account. 
The influence of target saturation becomes 
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most significant for target occupancies >50%, 
where a 1% increase in drug concentration 
leads to <0.5% increase in occupancy, while 
at target occupancies approaching 0%, a 1% 
increase in drug concentration leads to a 1% 
increase in target occupancy. The horizontal 
lines in FIG. 1c illustrate that slow drug–target 
dissociation is the main determinant of the 
duration of target occupancy if both the dis-
sociation rate constant and the target occu-
pancy have values such that: BF < 1 − koff /kel 
(in which BF is the target fraction bound). It 
should be noted that this equation is rewritten 
from an approximation of the simple drug–
target binding model and only holds for this 
model if the target concentration is lower than 
the ratio kel/kon, as described previously4. Of 
note, the target occupancy–time curves in 
FIG. 1b,c are independent of this approxima-
tion, as they are simulated with the original 
equations, not with the approximations. Only 
the horizontal lines in FIG. 1c are based on the 
approximation.
From this equation, it follows that when 
the clinical situation requires a high target 
occupancy (as can be expected especially for 
antagonists for chronic diseases with daily or 
less frequent dosing), then koff will need to 
be much smaller than kel for it to become the 
main determinant of the duration of target 
occupancy.
These findings can be applied directly to 
the selection of drug candidates. An example 
in which our insights could have been applied 
is the study of Lindström and colleagues9, 
which compared the in vivo drug effects of 
three neurokinin 1 (NK1) receptor antago-
nists with their pharmacokinetics. Aprepitant 
demonstrated a much longer duration of drug 
effect, which can clearly be attributed to tar-
get saturation, considering that the effect is 
close to 100% for a long time in the experi-
ment, followed by a steep decline. In contrast, 
the authors conclude that the duration of the 
effect of aprepitant cannot be explained by 
its pharmacokinetics. The other two com-
pounds in this study did not show this target 
saturation and the authors conclude that this 
is probably explained by their faster binding 
kinetics. However, our findings above indicate 
that the increased duration of the aprepitant 
effect is mainly due to its high brain concen-
trations compared with its affinity, which 
causes target saturation.
Our quantitative approximations can also 
be applied to the decision as to whether to 
consider drug–target residence time in hit 
and/or lead selection. For C-C chemokine 
receptor type 2 (CCR2) antagonists, an occu-
pancy of >90% is considered to be required 
for a sufficient drug effect. Based on the 
 Figure 1 | Simulation of the implications of high target occupancy for drug–target residence 
time. a | Model used in the simulations. Here, ka and kel represent the first-order absorption constant 
(3.0 h−1) and elimination rate constant, respectively, while kon and koff represent the second-order asso-
ciation rate constant and the first-order dissociation rate constant, respectively. b | Simulations of 
plasma drug concentrations (left panel) and the resulting target occupancy profiles (right panel) for 
different compounds. The solid lines represent the HIV protease inhibitors amprenavir (red), ataza-
navir (yellow) and lopinavir (green), with kon values of 1.1, 6.2 and 23 nM−1 h−1, respectively. The dotted 
lines represent hypothetical compounds with the same Kd values as atazanavir and lopinavir but the 
same koff value as amprenavir, leading to kon values of 44 (blue) and 176 (orange) nM
−1 h−1, respectively. 
The target concentration was set at 1 pM. The elimination rate constant was 0.082 h−1. The dose in the 
absorption compartment corresponds to an initial plasma concentration of 200 nM, if absorption 
would be immediate. All plasma concentration profiles overlap. For the associated differential equa-
tions, see Supplementary information S1, and for the R simulation script, see Supplementary informa-
tion S2. Similar simulations can be performed online (see Related links). c | Simulations of plasma drug 
concentrations (left panel) and the resulting target occupancy profiles (right panel) for different 
compounds. The solid lines represent the muscarinic receptor antagonists ipratropium (red), acli-
dinium (yellow) and PF-3635659 (green), with kon values of 15, 4.0 and 1.4 nM−1 h−1, respectively. The 
dotted lines represent hypothetical compounds with the same Kd values as aclidinium and 
PF-3635659 but the same koff value as ipratropium, leading to kon values of 198 (blue) and 218 (orange) 
nM−1 h−1, respectively. All plasma concentration profiles overlap. The concentration of the target (the 
muscarinic M3 receptor was set at 1 pM. The elimination rate constant was 0.69 h−1. The dose in the 
absorption compartment corresponds to an initial plasma concentration of 200 nM, if absorption is 
immediate. The dashed horizontal lines denote the situation in which the target fraction bound 
equals 1 − koff/kel (see text). Below that line, the condition is met for which koff is the main determinant 
of the decline rate of target occupancy.
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equation above, this means that the dissocia-
tion half-life needs to be 10 times larger than 
the plasma half-life in order for it to be the 
main determinant of target occupancy. As the 
plasma half-life of the CCR2 antagonist iden-
tified by Bot and colleagues was 11 hours10, 
this means that the dissociation half-life 
would need to be 110 hours or longer before 
it became the main determinant of the dura-
tion of drug effect. In combination with the 
knowledge that such long dissociation half-
lives are rarely observed4, this suggests that 
seeking to prolong the dissociation half-life 
should not be prioritized when searching for 
CCR2 antagonists with a prolonged duration 
of effect, or for other drug targets for which 
high occupancies are considered essential to 
achieve the desired pharmacological effect.
Conclusion
Target saturation is an important factor that 
should be included in the analysis of the influ-
ence of drug–target binding kinetics on tar-
get occupancy. By doing so, drug discovery 
scientists would be better equipped to decide 
on the relevance of drug–target binding 
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Absorption, binding and elimination model: https://
wilbertdewitte.shinyapps.io/absorption_binding_elimination
ALL LINKS ARE ACTIVE IN THE ONLINE PDF
kinetics for each specific project, depending 
on the required level of target occupancy and 
the (predicted) pharmacokinetics.
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